Skip to main content

Table 2 The Symptoms Recurrence rate after one month of discontinuation of the treatment Protocol and relation to demographic characteristic

From: Overactive bladder symptoms recurrence after sudden versus gradual weaning of Solifenacin

  Symptoms Recurrence P value
No
N = 48
Yes
N = 12
Treatment Protocol; n (%)
 Group I; n = 30 20 (66.7) 10 (33.3) 0.001*
 Group II; n = 30 28 (93.3) 2 (6.7)
Age; (years)
 qMean ± SD 40.04 ± 17.4 61.67 ± 12.1 0.001*
 95% CI1 for Mean
  Lower bound 35.00 54.00  
  Upper bound 45.08 69.32  
  Range (Max–Min) 65.00 (75–10) 35.00 (77–42)  
Gender; n (%)
 Male; n = 21 18 (85.7) 3 (14.3) 0.325a
 Female; n = 39 30 (76.9) 9 (23.1)  
  1. 195% Confidence Interval of Mean
  2. *P value ≤ 0.05 is considered significant by (independent sample t test)
  3. aP value > 0.05 is considered non-significant by (Chi-square test)